These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 9339198

  • 1. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
    Ferrero JM, Largillier R, Ramaioli A, Heudier P, Teissier E, Namer M.
    Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
    [Abstract] [Full Text] [Related]

  • 2. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK, Sorosky JI, Gelder MS, Buller RE, Anderson B, Wilkinson EJ, Benda JA, Morgan LS.
    Cancer; 1998 May 01; 82(9):1731-7. PubMed ID: 9576296
    [Abstract] [Full Text] [Related]

  • 3. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Onkologie; 2008 Jun 01; 31(6):315-20. PubMed ID: 18547972
    [Abstract] [Full Text] [Related]

  • 4. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M, Federico M, Liu PY, Hannigan E, Alberts D.
    Gynecol Oncol; 2006 Oct 01; 103(1):195-8. PubMed ID: 16595148
    [Abstract] [Full Text] [Related]

  • 5. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R.
    Gynecol Oncol; 1995 Jul 01; 58(1):42-7. PubMed ID: 7789889
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.
    Gynecol Oncol; 2007 Jan 01; 104(1):176-80. PubMed ID: 16996584
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F, Bădulescu A, Schenker M, Popescu CF, Stoica Z.
    Rom J Morphol Embryol; 2005 Jan 01; 46(4):329-34. PubMed ID: 16688372
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
    van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R.
    Gynecol Oncol; 2000 Dec 01; 79(3):444-50. PubMed ID: 11104617
    [Abstract] [Full Text] [Related]

  • 11. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
    Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR.
    Gynecol Oncol; 2004 Apr 01; 93(1):131-6. PubMed ID: 15047226
    [Abstract] [Full Text] [Related]

  • 12. Human tetranectin: methodological and clinical studies.
    Høgdall CK.
    APMIS Suppl; 1998 Apr 01; 86():1-31. PubMed ID: 9868384
    [Abstract] [Full Text] [Related]

  • 13. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
    Farzad M, De Luca MC, Rubino G, Pirtoli L, Pepi F, Sebaste L, Ponticelli P, Atzeni G, Maranzano E, Silvano G.
    Radiol Med; 2001 Apr 01; 102(1-2):72-7. PubMed ID: 11677442
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Value of serum CA(125) detection for predicting recurrence and prognosis in ovarian epithelial cancer].
    Wang XY, Ye J, Feng SW, Lü WG, Wan XY, Xie X.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Nov 01; 45(11):813-6. PubMed ID: 21211277
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Acta Obstet Gynecol Scand; 2008 Nov 01; 87(11):1136-42. PubMed ID: 18951217
    [Abstract] [Full Text] [Related]

  • 18. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.
    Gynecol Oncol; 1999 Mar 01; 72(3):278-87. PubMed ID: 10053096
    [Abstract] [Full Text] [Related]

  • 19. CA-125 AUC as a new prognostic factor for patients with ovarian cancer.
    Mano A, Falcão A, Godinho I, Santos J, Leitão F, Oliveira C, Caramona M.
    Gynecol Oncol; 2005 May 01; 97(2):529-34. PubMed ID: 15863156
    [Abstract] [Full Text] [Related]

  • 20. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G.
    Gynecol Oncol; 2001 May 01; 81(2):150-9. PubMed ID: 11330942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.